FDA clears MiniMed Fit tubeless insulin pump
The company plans a phased US launch in spring 2027 following clearance for users aged seven and older.

MiniMed has announced FDA clearance for MiniMed Fit, its first tubeless insulin pump. According to the announcement, it is cleared for people with type 1 and type 2 diabetes aged seven and older.
The manufacturer describes up to seven days of wear and a 300-unit reservoir. A compatible iOS or Android app controls the system, while SmartGuard provides automated insulin delivery. At commercial launch, users are expected to have a choice of Simplera Sync or Abbott’s Instinct sensor. A phased US rollout is planned for spring 2027.
Context and evidence
Clearance and launch are not the same event. The company describes manufacturing readiness and planned pharmacy distribution, not broad current availability. Real-world SmartGuard results cited in the source relate to that technology and should not automatically be interpreted as a standalone comparative trial of the new pump.
What it means
The clearance expands the planned choice of automated insulin delivery systems. Availability, compatibility and individual medical suitability still govern actual use; this news is not a treatment recommendation.
Primary source: Original announcement. This report is based on company statements, not an independent clinical assessment.
More from Regulation
AI illustrationFDA clears AI software for coronary CT analysis
Syngo.CT Coronary Cockpit analyzes plaque and supports intervention planning. The clearance applies to the US market.
AI illustrationHugo surgical robot gains US clearance for general surgery
Medtronic expands the US indications for its robotic-assisted surgery platform; clearance is not proof of superior outcomes.
AI illustrationPhilips submits helium-free 3T MRI platform to the FDA
BlueSeal Horizon is under review, not cleared; “helium-free” describes operation with helium sealed inside the magnet.